SEC14 like lipid binding 2Genealiases: C22orf6 · SPF · TAP · TAP1
Q-omics provides the consensus-scored SEC14L2 profile across patient tissues and cancer cell-line models. SEC14L2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SEC14L2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SEC14L2 RNA expression shows 18,212 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where SEC14L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC14L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC14L2 survival associations across molecular data types. SEC14L2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC14L2 RNA expression–survival associations across cancer types. High SEC14L2 expression shows unfavorable associations in HNSC, MESO and UVM, but favorable associations in BRCA, ESCA and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SEC14L2 RNA expression.
This table summarizes SEC14L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SEC14L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC14L2 shows higher tumor expression in KIRC, COAD, THCA, BLCA, LUAD and HNSC. The KIRC box plot shows higher SEC14L2 RNA expression in tumor versus normal tissue (log2 FC = +0.928, t-test p < 0.001).
This table shows molecular features associated with SEC14L2 in patient tissues and cancer cell lines. In patient samples, SEC14L2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC14L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
